来源：梅斯医学
本次会议将分别聚焦美国生物药研发与市场经验和中国生物药发展趋势，助力中国生物药的创新与发展，为美国大型药企和国内生物药企业提供更多的合作点，推动全球市场经济。会议将邀请国内外知名药企研发及市场负责人、国内外知名药物设计与研发专家、全球知名医药咨询公司及知识产权、投融资行业专业人士前来做报告。
会议基本情况
时 间
： 2017年 8月10-11日
地 点
：中国 杭州 和达希尔顿酒店
规 模
： 300人
主办单位
： 生物谷，杭州经济开发区
会议形式
：主题演讲、项目路演、圆桌讨论，workshop
大会部分嘉宾演讲摘要：
陈凯先
院士
中国科学院上海药物研究所
个人简介
：陈凯先，原籍江苏南京，生于重庆。1967年毕业于复旦大学。1982年和1985年在中国科学院上海药物研究所先后获得硕士和博士学位，博士生导师，所长。现任上海中医药大学校长、国家新药研究和开发专家委员会委员、中国科学院新药研究专家委员会委员、中国新医药博士联谊会理事长；
主要从事计算机辅助药物分子设计研究。进行有机小分子和生物大分子的结构和生物活性之间关系的研究，有活性的有机小分子结构预测和设计。
杨建国
CEO
Abpro-China
个人简介
：Dr. Jianguo (James) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China ( Abpro, a Biotech company based in Boston area, USA).
演讲题目：Innovative Antibody Drug Discovery Platform.
演讲摘要
：Abprodeveloped unique tech platform for innovative antibodydrugdiscovery, which can generatetherapeuticantibodiesfasterthan the curent antibodydiscoverysystems in biotech industry, and can shortentherapeuticantibodydevelopment timeline. This presentationwillarticulateAbpronovelantibody platform and Abprotherapeuticantibody pipeline, and exemples of development of noveltherapeuticantibodiesusingAbpro’s tech platform, and future strategic plans for therapeuticantibodydevelopment partnerships.
田文志
创始人
宜明昂科生物医药技术（上海）有限公司
个人简介
：Dr. Wenzhi Tian, 1000-Talent of Shanghai, is the founder and Chairman of ImmuneOnco Biopharma Co., Ltd, a start-up company in China, with primary focus of its R&D on tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANK) products that will meet the unmet medical needs both in China and global market.
演讲题目：Next Generation of Immune Checkpoint Inhibitors.
演讲摘要
：Tumor immunotherapy has proved to be promising treatments with long-lasting efficacy. However due to the low response rate (only 20-30% of response rate approximately), new molecules as well as new treatment approaches in which two or more drugs are combined are under development. Here we report several new molecules developed in our company that have robust anti-tumor activity in several xenograft tumor models. We believe these molecules have great potentials to be the first-in-class drugs in tumor therapy.
